Swissmedic
REGULATORY UPDATE
Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Published: 10/1/2026Detected: 10/1/2026
Summary preview
Clarifies or updates Swiss guidance on the conditions and documentation expectations for importing human medicinal products under Art. 14 para. 2 and 3 TPA (parallel import).
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
safety
labeling
#parallel import
#TPA Art. 14
#importation of medicinal products
#dossier requirements
#quality documentation
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Extended deadline for publishing officially mandated information materials on the electronic publication platform11/12/2026
- Designer drugs: FDHA brings further psychoactive substances under control11/10/2026
- NAD+ supplements: When lifestyle products have criminal consequences11/9/2026
- Publication eCTD v4.0 Implementation Guide Package v2.011/9/2026
- Save the Date: Clinical Trials Symposium 202711/4/2026